GOSS

Gossamer Bio Inc

10.65

Nov 09 • 3:59 PM ET +0.88 (8.96%)

10.60

Aftermarket • 7:30 PM ET -0.05 (-0.42%)

Healthcare Biotechnology USA Micro NASD

Peers: TENX INSM UTHR LQDA MNKD ROIV KROS SVRA MRK JNJ

| Held by: VTI VXF IBB VHT PRFZ ESSC IBBQ BIB

Scroll to Statements

Index	-
Market Cap	65.05M
Enterprise Value	48.09M
Income	-125.22M
Sales	53.29M
Book/sh	-15.39
Cash/sh	9.33
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	162
IPO	Feb 08, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	1.22
P/B	-
P/C	1.14
P/FCF	-
EV/EBITDA	-
EV/Sales	0.90
Quick Ratio	0.53
Current Ratio	0.53
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-55.67
EPS next Y	-10.52
EPS next Q	-3.79
EPS this Y	73.96%
EPS next Y	32.65%
EPS next 5Y	45.71%
EPS past 3/5Y	34.98% 26.82%
Sales past 3/5Y	- -
EPS Y/Y TTM	7.41%
Sales Y/Y TTM	32.43%
EPS Q/Q	54.54%
Sales Q/Q	-19.59%
Earnings	Aug 13 AMC
EPS/Sales Surpr.	35.19% 154.57%

Insider Own	8.34%
Insider Trans	0.00%
Inst Own	66.78%
Inst Trans	56.39%
ROA	-78.81%
ROE	-
ROIC	-
Gross Margin	98.25%
Oper. Margin	-297.67%
Profit Margin	-235.00%
SMA20	10.66%
SMA50	-1.03%
SMA200	-69.68%
Trades

Shs Outstand	6.11M
Shs Float	5.60M
Short Float	25.65%
Short Ratio	5.60
Short Interest	1.44M
52W High	309.60 -96.56%
52W Low	8.29 28.41%
Volatility	11.06% 9.31%
ATR (14)	0.99
RSI (14)	54.50
Beta	2.25
Rel Volume	0.91
Avg Volume	256.62K
Volume	234,756

Perf Week	12.65%
Perf Month	14.34%
Perf Quarter	-26.81%
Perf Half Y	-60.71%
Perf YTD	-95.71%
Perf Year	-94.36%
Perf 3Y	-75.81%
Perf 5Y	-98.98%
Perf 10Y	-
Recom	2.25
Target Price	95.40
Prev Close	9.77
Price	10.65
Change %	8.96%

Consensus

Buy

Avg. Price Target

$95.40

Implied Upside

+796.2%

Analysts13incl. previous ratings

Rating Distribution6 Buy · 6 Hold · 1 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 13, 2026	Initiated	CChardan Capital Markets	Buy	$160	+1,403.1%
Jul 28, 2026	Upgrade	LLeerink Partners	Market Perform → Outperform	$1	-90.6%
Mar 23, 2026	Downgrade	CCantor Fitzgerald	Overweight → Neutral
Feb 24, 2026	Downgrade	WWedbush	Outperform → Neutral	$1	-90.6%
Feb 24, 2026	Downgrade	LLeerink Partners	Outperform → Market Perform	$1	-90.6%
Feb 24, 2026	Downgrade	BBarclays	Overweight → Equal Weight	$0.30	-97.2%
Jan 28, 2026	Initiated	BBarclays	Overweight	$9	-15.5%
Sep 10, 2025	Upgrade	UUBS	Neutral → Buy	$9	-15.5%
Jul 14, 2025	Initiated	BScotiabank	Sector Outperform	$11	+3.3%
Jun 25, 2024	Initiated	OOppenheimer	Outperform	$9	-15.5%
Apr 05, 2024	Resumed	WWedbush	Outperform	$4	-62.4%
Jul 27, 2023	Downgrade	UUBS	Buy → Neutral	$8 → $1.25	-88.3%
Mar 07, 2023	Downgrade	RRaymond James	Outperform → Mkt Perform
Mar 01, 2023	Initiated	GGuggenheim	Neutral
Dec 07, 2022	Downgrade	SSMBC Nikko	Outperform → Neutral	$3	-71.8%
Dec 07, 2022	Downgrade	JJP Morgan	Neutral → Underweight
Dec 07, 2022	Downgrade	BBarclays	Overweight → Equal Weight	$18 → $2	-81.2%
Oct 20, 2022	Initiated	GGoldman	Buy	$22	+106.7%
Sep 21, 2022	Initiated	JJP Morgan	Neutral	$17	+59.7%
Sep 19, 2022	Initiated	WWedbush	Outperform	$24	+125.5%

Oct-13-26 09:43AM	Adobe downgraded, VF Corp. upgraded: Wall Street's top analyst calls (The Fly) +5.17%
Sep-23-26 04:01PM	Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension (Business Wire) -5.99%
Sep-16-26 04:01PM	Gossamer Bio Appoints Greg Ciongoli to Board of Directors (Business Wire) +5.59% +8.94%
Sep-11-26 08:00AM	Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split (Business Wire) -5.81%
Sep-09-26 09:00AM	Gossamer Bio Announces 1-for-80 Reverse Stock Split (Business Wire) -11.23%
08:00AM	Loading…
Sep-04-26 08:00AM	Gossamer Bio to Present at Cantor Global Healthcare Conference (Business Wire)
Aug-24-26 06:15AM	Gossamer Bio announces $250m in funding to advance seralutinib (Pharmaceutical Technology) +13.12%
Aug-21-26 09:49AM	Gossamer Bio Secures Up to $250 Million Private Placement to Fund Seralutinib Through Potential FDA Approval (InvestorsHub)
08:00AM	Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval (Business Wire)
Aug-13-26 04:10PM	Gossamer Bio: Q2 Earnings Snapshot (Associated Press) -9.45%
04:01PM	Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update (Business Wire)
Jul-27-26 09:33AM	Gossamer Bio shares jump after FDA update and seralutinib rights return (InvestorsHub) +46.62%
07:00AM	Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update (Business Wire)
Jul-01-26 09:00AM	Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants (Business Wire)
Jun-17-26 06:19PM	Gossamer Bio Inc (GOSS) Q1 2026 Earnings Call Highlights: Strategic Debt Reduction and ... (GuruFocus.com) +6.74% -6.15%
08:00AM	Loading…
08:00AM	Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes (Business Wire)
Jun-03-26 08:00AM	Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes (Business Wire) -5.94%
Jun-02-26 08:00AM	Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes (Business Wire)
Jun-01-26 03:50AM	Gossamer Bio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - GOSS (PR Newswire) -14.21%
May-18-26 10:14AM	Gossamer Bio Shares Decline After Wider-Than-Expected Q1 Loss Despite Revenue Beat (GOSS) (InvestorsHub) -43.32%
07:05AM	Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support (Business Wire)
07:00AM	Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update (Business Wire)
May-15-26 06:21PM	Gossamer Bio: Q1 Earnings Snapshot (Associated Press)
07:01AM	Gossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026 (Business Wire)
Apr-10-26 07:53AM	Shareholders who lost money in Gossamer Bio, Inc (NASDAQ: GOSS) Should Contact Wolf Haldenstein Immediately (PR Newswire) +10.20%
Apr-03-26 07:30AM	Gossamer Bio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights GOSS (Business Wire)
Mar-25-26 09:00AM	GOSS: Announces Topline Results for Phase 3 PROSERA Trial -- LEVI & KORSINSKY, LLP (PR Newswire) +10.61%
Mar-17-26 04:08PM	Gossamer Bio: Q4 Earnings Snapshot (Associated Press Finance) -7.99%
04:01PM	Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update (Business Wire)
Mar-09-26 10:00AM	Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks) +10.90%
06:46AM	Loading…
Mar-07-26 06:46AM	Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q1 (Benzinga)
Mar-05-26 10:00AM	Earnings Preview: Gossamer Bio (GOSS) Q4 Earnings Expected to Decline (Zacks) -10.03%
Mar-04-26 06:50PM	GOSS: Announces Topline Results for Phase 3 PROSERA Trial -- LEVI & KORSINSKY, LLP (PR Newswire) +23.40%
Feb-26-26 12:15PM	Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +5.76%
09:55AM	Here's Why Gossamer Bio (GOSS) Is a Great 'Buy the Bottom' Stock Now (Zacks)
09:35AM	Gossamer Bio (GOSS) Loses 85% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Feb-25-26 05:51AM	Gossamer Bio (GOSS) Reports Topline Phase 3 Results for Seralutinib in Pulmonary Arterial Hypertension (Insider Monkey) -8.50%
Feb-24-26 09:40AM	Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
09:39AM	Qualcomm, Booking Holdings upgraded: Wall Street's top analyst calls (The Fly)
06:00AM	Novo to cut GLP-1 drug prices; Palvella soars on study data (BioPharma Dive)
Feb-23-26 01:13PM	Gossamer Bios Phase 3 PROSERA PAH Trial Misses Primary Endpoint Despite Numerical 6MWD Gain (MarketBeat) -80.13%
09:57AM	Gossamer Bio Plans FDA Talks After Narrow Miss In Key Pivotal Study, Stock Sinks (Benzinga)
08:00AM	Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension (Business Wire)
Feb-06-26 11:02AM	Analysts Remain Bullish on Gossamer Bio (GOSS) Citing Undervaluation (Insider Monkey) -7.19%
Jan-08-26 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-21-25 07:31AM	Gossamer Bio (GOSS) Sees Strong Analyst Confidence Amid Seralutinib Progress and Upcoming PROSERA Data (Insider Monkey)
Dec-15-25 11:11PM	Oppenheimer Confident in Positive PROSERA Trial Readout in February 2026 for Gossamer Bio (GOSS) (Insider Monkey) +5.28% -6.07%
Dec-11-25 06:41PM	Xoma Crumbles And Partner Rezolute Collapses On Failed Insulin Disease Drug (Investor's Business Daily)
Dec-09-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-24-25 04:01PM	Gossamer Bio to Participate in Upcoming Investor Conferences (Business Wire)
Nov-07-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.08%
07:31AM	Gossamer Bio to Participate in Upcoming Investor Conferences (Business Wire)
Nov-05-25 05:35PM	Gossamer Bio (GOSS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:29PM	Gossamer Bio: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Sep-25-25 07:41AM	Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital (PR Newswire) -7.02%
07:31AM	Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On-Demand Vardenafil for Pulmonary Hypertension (Business Wire)
Sep-23-25 07:22PM	Gossamer Bio, Inc. (GOSS) Stock Jumps 18% on FDA Updates and Seralutinib Progress (Insider Monkey)
Sep-22-25 07:31AM	Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025 (Business Wire)
Sep-11-25 01:15PM	H.C. Wainwright Asserts Buy Stance on Gossamer Bio Inc. (GOSS) on Pulmonary Arterial Hypertension Drug Prospects (Insider Monkey) +11.25%
03:31AM	Piper Sandler Reiterates Buy as Seralutinib Momentum Boosts Gossamer (GOSS) Multibagger Case (Insider Monkey)
Sep-10-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +12.27%
Aug-29-25 07:31AM	Gossamer Bio to Present at Upcoming Investor Conferences (Business Wire)
Aug-19-25 12:06AM	H.C. Wainwright and Leerink Partners Reiterate 'Buy' Ratings on Gossamer Bio, Inc. (GOSS) (Insider Monkey)
Aug-07-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -12.12%
Aug-05-25 05:55PM	Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -8.33%
04:53PM	Gossamer Bio: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update (Business Wire)
08:40AM	Harmony Biosciences Holdings, Inc. (HRMY) Misses Q2 Earnings and Revenue Estimates (Zacks)
Jul-30-25 07:05AM	GSK (GSK) Q2 Earnings and Revenues Beat Estimates (Zacks) +6.12%
Jun-24-25 12:46PM	Gossamer Bio Completes Enrollment for Phase 3 PROSERA Study of PAH Drug Seralutinib (Insider Monkey)
Jun-16-25 07:31AM	Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH (Business Wire)
Jun-06-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.56%
May-21-25 07:00AM	Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream (GlobeNewswire)
May-16-25 09:11AM	Q1 2025 Gossamer Bio Inc Earnings Call (Thomson Reuters StreetEvents)
03:15AM	Gossamer Bio Inc (GOSS) Q1 2025 Earnings Call Highlights: Strategic Progress Amid Financial ... (GuruFocus.com)
May-15-25 05:15PM	Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:09PM	Gossamer Bio: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study (Business Wire)
May-14-25 09:45AM	What To Expect From Gossamer Bio Inc (GOSS) Q1 2025 Earnings (GuruFocus.com) -7.34%
May-12-25 04:01PM	Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025 (Business Wire)
May-07-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
04:01PM	Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference (Business Wire)
May-02-25 01:21PM	Gossamer Bio: Initiating Hold As Late-Stage Data Nears Inflection (Seeking Alpha) +11.32%
Apr-16-25 09:57AM	Is Gossamer Bio Inc. (NASDAQ:GOSS) the Best Penny Stock to Invest in Under $1? (Insider Monkey)
Apr-09-25 09:44AM	Gossamer Bio, Inc. (GOSS): Among Stocks Under $10 that Will Triple (Insider Monkey) +11.76%
Apr-08-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-27-25 09:45AM	Is Gossamer Bio Inc. (GOSS) the Popular Penny Stock on Robinhood to Watch? (InsiderMonkey)
Mar-26-25 01:38PM	Is Gossamer Bio, Inc. (GOSS) The Hot Biotech Stock Under $5? (InsiderMonkey) -7.81%
Mar-23-25 08:41AM	Gossamer Bio (GOSS): Among the Penny Stocks With Huge Upside Potential According to Analysts (InsiderMonkey)
Mar-13-25 05:10PM	Gossamer Bio (GOSS) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +11.54%
04:06PM	Gossamer Bio: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update (Business Wire)
Mar-07-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-19-25 06:00AM	Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now (GlobeNewswire)
Feb-07-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +10.38%
Feb-03-25 07:01AM	Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress (Business Wire)
Jan-28-25 07:01AM	Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress (Business Wire)
Jan-07-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.41%
09:19AM	Why Gossamer Bio, Inc. (GOSS) Is Among the Best Penny Stocks to Invest In According to Media? (Insider Monkey)

Show Previous News

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 26, 2015 and is headquartered in San Diego, CA.

Co-FounderMr. Faheem Hasnain

COO & CFOMr. Bryan Giraudo

Chief Commercial OfficerMr. Robert Paul Smith Jr.

Executive Vice PresidentMr. Christian Waage J.D.

Senior Vice President of MarketingMs. Jeanine Anthony

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GOSS

Gossamer Bio Inc

Upgrade your Finviz experience